When researchers encounter CJC-1295 for the first time, one question consistently arises: does the DAC modification matter, and which variant is right for the research protocol at hand? The answer is not simply a matter of convenience the presence or absence of the Drug Affinity Complex (DAC) fundamentally changes the pharmacokinetic profile, the pattern of growth hormone (GH) secretion, and the biological information the experiment can generate. This article provides a technical comparison of CJC-1295 No DAC (Modified GRF 1-29) and CJC-1295 With DAC to help researchers understand the mechanistic distinctions and select the appropriate compound for their investigative goals.

CJC-1295 variants are studied in laboratory settings for their distinct pharmacokinetic profiles.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), specifically derived from the biologically active N-terminal fragment GHRH(1-29). Native GHRH has a plasma half-life of approximately 7 minutes due to rapid cleavage by the enzyme dipeptidyl peptidase IV (DPP-IV). CJC-1295 addresses this limitation through four strategic amino acid substitutions — Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 — which confer resistance to DPP-IV-mediated degradation while preserving high-affinity binding to the GHRH receptor (GHRHR) on anterior pituitary somatotrophs.

Both CJC-1295 variants share this tetrasubstituted backbone. The critical difference lies in what happens after this point: one variant incorporates a Drug Affinity Complex that dramatically extends its biological activity, while the other does not.

The DAC Modification: How It Works

The Drug Affinity Complex (DAC) is a maleimide-lysine moiety added to the C-terminal extension of the CJC-1295 backbone. Once administered, this maleimide group undergoes a Michael addition reaction with the free cysteine-34 residue of endogenous serum albumin, forming a stable covalent bond. Since circulating albumin has a half-life of approximately 19 days, this bond effectively converts albumin into a long-lived circulating reservoir for the peptide releasing biologically active CJC-1295 gradually as the albumin-peptide bond undergoes slow hydrolysis.

Research data from Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) confirmed that at least 90% of administered CJC-1295 with DAC binds covalently to albumin, with negligible free peptide remaining in circulation. This produces an estimated half-life of 5.8 to 9.2 days in human research subjects a dramatic extension from the approximately 30-minute half-life of the No DAC variant.

The DAC modification enables covalent albumin binding, transforming CJC-1295 into a sustained-release depot compound.

 

The DAC modification enables covalent albumin binding, transforming CJC-1295 into a sustained-release depot compound.

Pharmacokinetic Comparison

The pharmacokinetic profiles of the two variants represent their most significant distinction for experimental design purposes. CJC-1295 No DAC produces a rapid, high-amplitude GH pulse that returns to baseline within 2-3 hours, closely mimicking the natural ultradian GHRH pulses that originate from the hypothalamus. CJC-1295 with DAC produces a sustained, tonic elevation of GH and IGF-1 that persists for several days per administration.

Parameter

CJC-1295 No DAC (Mod GRF 1-29)

CJC-1295 With DAC

Half-Life

~25-30 minutes

~5.8-9.2 days

Albumin Binding

None

Covalent (Cys-34)

GH Secretion Pattern

Pulsatile, physiological

Sustained tonic elevation

IGF-1 Response

Short-term spikes, returns to baseline

Sustained multi-day elevation

DPP-IV Resistance

Moderate (tetrasubstitution)

High (tetrasubstitution + albumin protection)

Receptor Sensitivity

Better preserved (pulsatile pattern)

Potential downregulation risk (chronic)

Experimental Control

High (short window, timed protocols)

Lower (prolonged activity, harder to stop)

Molecular Weight

~3,367 Da

~3,647 Da

GH Secretion Patterns: Pulsatile vs Sustained

Understanding the difference between pulsatile and sustained GH secretion is fundamental to selecting the correct variant. Under normal physiological conditions, GHRH is released from the hypothalamus in discrete pulses typically 8 to 12 per day which drive corresponding GH pulses from the pituitary. This ultradian rhythm is not simply a convenience of biology; the pulsatile pattern is critical for maintaining GHRHR sensitivity and for producing the distinct hepatic and peripheral effects of GH on tissue metabolism and IGF-1 production.

CJC-1295 No DAC preserves this pulsatile model. Each administration produces an acute GH surge that clears within 2-3 hours, allowing the normal negative-feedback loop (somatostatin, IGF-1) to restore baseline GH tone before the next pulse. This makes it the preferred tool for research examining acute somatotroph signalling, GH pulse amplitude modulation, and combination protocols with GHS-R1a agonists such as Ipamorelin.

CJC-1295 with DAC, by contrast, bypasses this rhythm entirely. The sustained albumin-depot release maintains continuous GHRHR stimulation, overriding the normal somatostatin-driven off-phases. This produces a chronically elevated GH and IGF-1 environment that is distinctly non-physiological a research model suited to studying the effects of prolonged, uninterrupted GH axis activation rather than normal pulsatile biology.

The pulsatile vs sustained GH secretion distinction has significant implications for experimental design in GH axis research.

 

The pulsatile vs sustained GH secretion distinction has significant implications for experimental design in GH axis research.

Research Applications: Which Variant for Which Protocol?

When to Use CJC-1295 No DAC

  • Pulsatile GH secretion studies replicating and studying the physiological ultradian GH rhythm in preclinical models
  • Combination GHRHR + GHS-R1a protocols paired with Ipamorelin for dual-pathway acute GH pulse amplification research
  • Acute neuroendocrine signalling short-window experiments requiring precise timing of GHRHR activation and deactivation
  • Receptor sensitivity studies experiments where GHRHR downregulation must be minimised across the duration of the study
  • Structure-activity relationship work evaluating how DPP-IV resistance substitutions affect GHRHR binding kinetics without the confound of albumin conjugation

When to Use CJC-1295 With DAC

  • Chronic GH axis elevation models longitudinal studies where sustained, multi-day GH and IGF-1 elevation is required
  • Once-weekly dosing protocols research models that require minimal intervention frequency
  • IGF-1 response studies examining sustained hepatic IGF-1 production over days or weeks rather than hours
  • Long-term body composition research preclinical models evaluating the downstream metabolic effects of chronic GH axis stimulation

A Note on Combination Research: CJC-1295 No DAC + Ipamorelin

One of the most commonly studied peptide combinations in the GH axis research literature pairs CJC-1295 No DAC with Ipamorelin, a selective GHS-R1a (ghrelin receptor) agonist. These compounds act through distinct but complementary receptor pathways: CJC-1295 No DAC activates GHRHR on pituitary somatotrophs, while Ipamorelin activates GHS-R1a a second, independent stimulatory pathway for GH secretion.

Research models combining both peptides study the additive effects of simultaneous GHRHR and GHS-R1a activation on pulsatile GH release amplitude. Because both act through different receptor mechanisms, their combined effect on GH secretion is studied as potentially greater than either compound alone. Crucially, CJC-1295 No DAC’s pulsatile profile is considered preferable in these combination protocols, as it preserves the acute pulse structure that makes the combination pharmacologically meaningful.

CJC-1295 No DAC is frequently studied alongside Ipamorelin for complementary GHRHR and GHS-R1a receptor pathway activation.

CJC-1295 No DAC is frequently studied alongside Ipamorelin for complementary GHRHR and GHS-R1a receptor pathway activation.

Storage and Handling

  • Store lyophilized peptide at 20°C or below prior to reconstitution
  • Avoid repeated freeze-thaw cycles
  • Protect from direct light, humidity, and room temperature exposure
  • Reconstitute using sterile bacteriostatic water under aseptic laboratory conditions
  • Once reconstituted, store at 4°C and use within recommended research timeframes

Frequently Asked Questions

What is the main difference between CJC-1295 No DAC and CJC-1295 with DAC?

The core difference is the Drug Affinity Complex (DAC) modification. CJC-1295 with DAC includes a maleimide-lysine group that binds covalently to serum albumin after administration, extending its half-life to approximately 6-9 days and producing sustained GH elevation. CJC-1295 No DAC lacks this modification, resulting in a ~30 minute half-life and producing acute, pulsatile GH release that closely mimics natural GHRH secretion patterns.

Which CJC-1295 variant is better for pulsatile GH research?

CJC-1295 No DAC (Modified GRF 1-29) is the preferred variant for pulsatile GH secretion research. Its short half-life produces acute GH pulses that return to baseline within 2-3 hours, accurately replicating the physiological ultradian GH rhythm and preserving the normal negative-feedback dynamics of the somatotropic axis. CJC-1295 with DAC overrides this rhythm with sustained tonic GH elevation, making it less suitable for studies where physiological pulsatility is the research variable.

What is Modified GRF 1-29 and is it the same as CJC-1295 No DAC?

Yes, Modified GRF 1-29 (Mod GRF 1-29) is an alternate name for CJC-1295 No DAC. Both refer to the same tetrasubstituted GHRH(1-29) analogue with DPP-IV-resistant amino acid modifications but without the DAC albumin-binding moiety. The “Modified GRF 1-29” naming convention is used by researchers to distinguish it clearly from the DAC-containing variant.

Why is CJC-1295 No DAC used with Ipamorelin in research?

CJC-1295 No DAC activates the GHRH receptor (GHRHR) on pituitary somatotrophs, while Ipamorelin activates the GHS-R1a (ghrelin receptor) two independent GH-stimulatory pathways. Combination protocols study whether simultaneous activation of both pathways produces additive or synergistic effects on pulsatile GH pulse amplitude. CJC-1295 No DAC is preferred over the DAC variant in these protocols because its pulsatile pharmacokinetic profile is compatible with the acute-response design of combination GH axis research.

Does CJC-1295 No DAC cause GHRH receptor downregulation?

Research models suggest CJC-1295 No DAC carries a lower risk of GHRHR downregulation compared to the DAC variant, precisely because its pulsatile activity pattern allows receptor recovery during the off-phases between pulses consistent with normal physiological GHRH signalling. CJC-1295 with DAC’s continuous receptor stimulation is associated with greater risk of GHRHR desensitisation over extended research protocols.

Scientific References

  1. Teichman et al. (2006) Prolonged Stimulation of GH and IGF-1 Secretion by CJC-1295, Journal of Clinical Endocrinology and Metabolism
  2. Jetté et al. (2006) Once-daily administration of CJC-1295, American Journal of Physiology: Endocrinology and Metabolism
  3. CJC-1295 Pharmacokinetics Research Overview, Palmetto Peptides 2026

Research Use Disclaimer: All products discussed in this article are intended strictly for in vitro laboratory research and scientific investigation by qualified professionals. They are not approved for human consumption, medical treatment, or veterinary use. NeuroPept Labs products are sold for research purposes only.